1-3 of 3
David Daniely
Close
Sort by
Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4352.
https://doi.org/10.1182/blood-2019-131324
Published: 2019
Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4402.
https://doi.org/10.1182/blood-2019-130888
Published: 2019
Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ning Xu, PhD, Nicole Ng, BS, Mingjie Li, BS, Erin Yu, BS, Eric Sanchez, BA, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Haiming Chen, MD PhD, James R. Berenson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1824.
https://doi.org/10.1182/blood-2019-131047
Published: 2019